Practice guidelines for pharmacists: The pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
作者信息
Bornstein Carolyn, Craig Marie, Tin Diane
机构信息
The Arthritis Program, Southlake Regional Health Centre, Newmarket, Ontario.
出版信息
Can Pharm J (Ott). 2014 Mar;147(2):97-109. doi: 10.1177/1715163514521377.
Abstract
摘要
相似文献
1
Practice guidelines for pharmacists: The pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.药剂师实践指南：使用传统和生物改善病情抗风湿药物对类风湿关节炎进行药物治疗管理。
Can Pharm J (Ott). 2014 Mar;147(2):97-109. doi: 10.1177/1715163514521377.
2
Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety.加拿大风湿病学会关于传统和生物改善病情抗风湿药物治疗类风湿关节炎的药物治疗建议：第二部分安全性。
J Rheumatol. 2012 Aug;39(8):1583-602. doi: 10.3899/jrheum.120165. Epub 2012 Jun 15.
3
Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.加拿大风湿病学会关于传统和生物改善病情抗风湿药物治疗类风湿关节炎的药物治疗建议。
J Rheumatol. 2012 Aug;39(8):1559-82. doi: 10.3899/jrheum.110207. Epub 2011 Sep 15.
4
Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.类风湿关节炎和血清阴性关节炎中除甲氨蝶呤之外的改善病情抗风湿药。
Curr Opin Rheumatol. 2008 May;20(3):251-6. doi: 10.1097/BOR.0b013e3282fb7caa.
5
Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.在一组接受生物改善病情抗风湿药或托法替布治疗的类风湿关节炎患者中医疗资源的使用情况。
Clin Rheumatol. 2021 Apr;40(4):1273-1281. doi: 10.1007/s10067-020-05432-6. Epub 2020 Sep 30.
6
Safety and Effectiveness of Biologic Disease-Modifying Antirheumatic Drugs in Older Patients with Rheumatoid Arthritis: A Prospective Cohort Study.生物制剂类改善病情抗风湿药物在老年类风湿关节炎患者中的安全性和有效性：一项前瞻性队列研究。
Drugs Aging. 2020 Dec;37(12):899-907. doi: 10.1007/s40266-020-00801-x. Epub 2020 Nov 18.
7
German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.德国指南：传统与生物改善病情抗风湿药物序贯治疗类风湿关节炎。
Rheumatol Int. 2014 Jan;34(1):1-9. doi: 10.1007/s00296-013-2848-3. Epub 2013 Aug 14.
8
Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.调查德克萨斯州类风湿性关节炎医疗补助受助者开始使用生物性改善病情抗风湿药物的时间以及药物依从性和持续性。
Clin Ther. 2016 Mar;38(3):646-54. doi: 10.1016/j.clinthera.2016.01.022. Epub 2016 Feb 18.
9
An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.根据风湿病学家和药剂师的意见，对改善病情抗风湿药与非抗风湿药之间药物相互作用的临床意义进行循证评估。
Clin Ther. 2009 Aug;31(8):1737-46. doi: 10.1016/j.clinthera.2009.08.009.
10
Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?传统抗风湿病情改善药（DMARDs）在类风湿关节炎治疗中是否仍有作用？
Curr Opin Rheumatol. 2003 May;15(3):185-92. doi: 10.1097/00002281-200305000-00003.
引用本文的文献
1
Sulforaphane Modulates Joint Inflammation in a Murine Model of Complete Freund's Adjuvant-Induced Mono-Arthritis.萝卜硫素调节完全弗氏佐剂诱导的单关节炎小鼠模型中的关节炎症。
Molecules. 2018 Apr 24;23(5):988. doi: 10.3390/molecules23050988.
2
Clearing up potential misconceptions about the treatment of rheumatoid arthritis and the use of methotrexate in combination therapy.澄清关于类风湿关节炎治疗以及甲氨蝶呤在联合治疗中使用的潜在误解。
Can Pharm J (Ott). 2018 Feb 9;151(2):94-97. doi: 10.1177/1715163518756679. eCollection 2018 Mar-Apr.
本文引用的文献
1
Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort.通过比较加拿大早期关节炎队列中不同站点的治疗差异，确定早期类风湿关节炎的最佳实践。
J Rheumatol. 2013 Nov;40(11):1823-30. doi: 10.3899/jrheum.121316. Epub 2013 Sep 15.
2
Polypharmacy of osteoarthritis: the perfect intestinal storm.骨关节炎的多种药物治疗：完美的肠道风暴。
Dig Dis Sci. 2013 Nov;58(11):3088-93. doi: 10.1007/s10620-013-2777-8. Epub 2013 Jul 25.
3
Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review.托珠单抗治疗类风湿关节炎的当前观点：综述
Patient Prefer Adherence. 2013 Jul 4;7:653-66. doi: 10.2147/PPA.S41433. Print 2013.
4
Systemic methotrexate therapy for psoriasis: past, present and future.系统性甲氨蝶呤治疗银屑病：过去、现在和未来。
Clin Exp Dermatol. 2013 Aug;38(6):573-88. doi: 10.1111/ced.12062.
5
Vascular effects of nonsteroidal antiinflammatory drugs.非甾体抗炎药的血管作用。
Joint Bone Spine. 2013 Jul;80(4):358-62. doi: 10.1016/j.jbspin.2012.12.002. Epub 2013 Jun 21.
6
Non-steroidal anti-inflammatory drugs (NSAIDs).非甾体抗炎药（NSAIDs）。
BMJ. 2013 Jun 11;346:f3195. doi: 10.1136/bmj.f3195.
7
Therapies for active rheumatoid arthritis after methotrexate failure.甲氨蝶呤治疗失败后的活动性类风湿关节炎治疗方法。
N Engl J Med. 2013 Jul 25;369(4):307-18. doi: 10.1056/NEJMoa1303006. Epub 2013 Jun 11.
8
Role of ambulatory blood pressure monitoring in hypertension and diabetes.动态血压监测在高血压和糖尿病中的作用。
Curr Hypertens Rep. 2013 Jun;15(3):137-42. doi: 10.1007/s11906-013-0352-5.
9
Methotrexate and trimethoprim-sulphamethoxazole: extremely serious and life-threatening combination.甲氨蝶呤和甲氧苄啶-磺胺甲噁唑：极其严重且危及生命的组合。
J Clin Pharm Ther. 2013 Jun;38(3):203-5. doi: 10.1111/jcpt.12060. Epub 2013 Mar 22.
10
Clinical and causality assessment in herbal hepatotoxicity.草药性肝毒性的临床与因果关系评估。
Expert Opin Drug Saf. 2013 May;12(3):339-66. doi: 10.1517/14740338.2013.774371. Epub 2013 Mar 5.
Zotero 插件